Literature DB >> 11790644

The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis.

Darryl C Zeldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11790644     DOI： 10.1164/ajrccm.165.2.2111077b

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner.

Authors:  Min Soo Park; Myung Hyun Sohn; Kyu-Earn Kim; Moon Sung Park; Ran Namgung; Chul Lee
Journal:  Lung       Date:  2010-11-05       Impact factor: 2.584

Review 3.  The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.

Authors:  Nohora Cristina Ayola-Serrano; Namrata Roy; Zareena Fathah; Mohammed Moustapha Anwar; Bivek Singh; Nour Ammar; Ranjit Sah; Areej Elba; Rawan Sobhi Utt; Samuel Pecho-Silva; Alfonso J Rodriguez-Morales; Kuldeep Dhama; Sadeq Quraishi
Journal:  Inflamm Res       Date:  2021-06-04       Impact factor: 6.986
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.